跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
KADCYLA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
KADCYLA
Authorized
STANDARD
KADCYLA
Hoffmann-La Roche Limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
b6e8b036a691f2db
Company
Hoffmann-La Roche Limited
Type
Standard
Approval Details
Approval Id
b6e8b036a691f2db
Drug Approval Canada Name
KADCYLA
Product Name
KADCYLA
Status
Marketed
Status Date
2018-10-24
Original Market Date
2018-10-24
Din
02473224
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
10:00.00
Atc Original
L01FD03 TRASTUZUMAB EMTANSINE
Atc Name
l 01 fd 03
Aig Number
0154730003
Company Name
Hoffmann-La Roche Limited
Company Address
7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8
Active Ingredients
TRASTUZUMAB EMTANSINE
160 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
b6e8b036a691f2db
Type
Standard
Back to Health Canada Approvals